PAR — Paradigm Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- AU$143.29m
- AU$135.35m
- AU$8.12m
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt
Brief: Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 Million
Australia's Paradigm Biopharma rises on signing licensing deal for animal drug
Brief: Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement
Brief: Paradigm Biopharmaceuticals Posts FY Loss Attributable Of A$18.8 Million
Australia's Paradigm Biopharma gains on funds to advance clinical trial
Brief: Paradigm Biopharmaceuticals Secures USD$27 Million Convertible Note Facility
Brief: Paradigm Biopharmaceuticals Says US Ethics Approval Received For Para_Oa_012 Phase 3 Trial
Brief: Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 Million
Australia's Paradigm Biopharma falls on discounted placement
Brief: Paradigm Biopharmaceuticals Announces A$16M Placement
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Brief: Paradigm Biopharmaceuticals Confirms Submission To US FDA To Progress Phase 3 OA Program
Brief: Paradigm Biopharmaceuticals HY Net Loss Attributable A$49.0 Million
Australia's Paradigm Biopharmaceuticals falls as HY losses widen
Australia's Paradigm Biopharmaceuticals tumbles on discounted raise